Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease

被引:84
|
作者
Fukuda, K
Vishnuvardhan, D
Sekiya, S
Hwang, J
Kakiuchi, N
Kazunari, T
Shimotohno, K
Kumar, PKR
Nishikawa, S [1 ]
机构
[1] MITI, AIST, Natl Inst Biosci & Human Technol, Tsukuba Sci City 3058566, Japan
[2] Univ Tsukuba, Inst Appl Biochem, Tsukuba Sci City, Japan
[3] MITI, AIST, Natl Inst Adv Interdisciplinary Res, Tsukuba Sci City, Japan
[4] Kyoto Univ, Inst Virus Res, Kyoto, Japan
来源
EUROPEAN JOURNAL OF BIOCHEMISTRY | 2000年 / 267卷 / 12期
关键词
HCV; RNA aptamer; SELEX; NS3 serine protease;
D O I
10.1046/j.1432-1327.2000.01400.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nonstructural protein 3 (NS3) from hepatitis C virus (HCV) is a serine protease that provides an essential function in maturation of the virus by cleaving the nonstructural regions of the viral polyprotein. The goal of this work was to isolate RNA aptamers that bind specifically to the NS3 protease active site in the truncated polypeptide Delta NS3. RNA aptamers were selected in vitro by systematic evolution of ligands by exponential enrichment (SELEX). The RNA pool for SELEX had a 30-nucleotide randomized core region. After nine selection cycles, a pool of Delta NS3-specific RNA aptamers were obtained. This RNA pool included 45 clones that divided into three main classes (G9-I, II and III). These classes include the conserved sequence GA(A/U)UGGGAC. These aptamers bind to Delta NS3 with a binding constant of about 10 nM and inhibit approximately 90% of the protease activity of Delta NS3 and MBP-NS3 (full-length of NS3 fused with maltose binding protein). In addition, these aptamers inhibited approximately 70% of the MBP-NS3 protease activity in the presence of the NS4A peptide P41. G9-I aptamer appeared to be a noncompetitive inhibitor for Delta NS3 with a K-i approximate to 100 nM in the presence of P41. These results suggest that the pool of selected aptamers have potential as anti-HCV compounds. Mutational analysis of the G9-I aptamer demonstrated that the sequences required for protease inhibition are in stem I, stem III and loop III of the aptamer. These regions include the conserved sequence GA(A/U)UGGGAC.
引用
收藏
页码:3685 / 3694
页数:10
相关论文
共 50 条
  • [41] In vivo determination of substrate specificity of hepatitis C virus NS3 protease:: Genetic assay for site-specific proteolysis
    Kim, SY
    Park, KW
    Lee, YJ
    Back, SH
    Goo, JH
    Park, OK
    Jang, SK
    Park, WJ
    ANALYTICAL BIOCHEMISTRY, 2000, 284 (01) : 42 - 48
  • [42] Construction of hepatitis C-SIN virus recombinants with replicative dependency on hepatitis C virus serine protease activity
    Cho, YG
    Moon, HS
    Sung, YC
    JOURNAL OF VIROLOGICAL METHODS, 1997, 65 (02) : 201 - 207
  • [43] Isolation and characterization of 2′-F-RNA aptamers against whole HIV-1 subtype C envelope pseudovirus
    London, Grace M.
    Mayosi, Bongani M.
    Khati, Makobetsa
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 456 (01) : 428 - 433
  • [44] Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor
    Heintges, T
    Encke, J
    Putlitz, JZ
    Wands, JR
    JOURNAL OF MEDICAL VIROLOGY, 2001, 65 (04) : 671 - 680
  • [45] Selection and characterization of RNA aptamers to the RNA-dependent RNA polymerase from foot-and-mouth disease virus
    Ellingham, Mark
    Bunka, David H. J.
    Rowlands, David J.
    Stonehouse, Nicola J.
    RNA, 2006, 12 (11) : 1970 - 1979
  • [46] Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines
    Friborg, Jacques
    Lin, Baiqing
    Chen, Chaoqun
    McPhee, Fiona
    VIROLOGY, 2013, 444 (1-2) : 384 - 393
  • [47] Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease
    Rajagopalan, Ravi
    Pan, Lin
    Schaefer, Caralee
    Nicholas, John
    Lim, Sharlene
    Misialek, Shawn
    Stevens, Sarah
    Hooi, Lisa
    Aleskovski, Natalia
    Ruhrmund, Donald
    Kossen, Karl
    Huang, Lea
    Yap, Sophia
    Beigelman, Leonid
    Serebryany, Vladimir
    Liu, Jyanwei
    Sastry, Srikonda
    Seiwert, Scott
    Buckman, Brad
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (01)
  • [48] Smallmolecule inhibitors of hepatitis C virus (HCV) nonstructural protein 5A (NS5A): a patent review (20102015)
    Ivanenkov, Yan A.
    Aladinskiy, Vladimir A.
    Bushkov, Nikolay A.
    Ayginin, Andrey A.
    Majouga, Alexander G.
    Ivachtchenko, Alexandre V.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2017, 27 (04) : 401 - 414
  • [49] Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A
    Hiet, Marie-Sophie
    Bauhofer, Oliver
    Zayas, Margarita
    Roth, Hanna
    Tanaka, Yasuhito
    Schirmacher, Peter
    Willemsen, Joschka
    Gruenvogel, Oliver
    Bender, Silke
    Binder, Marco
    Lohmann, Volker
    Lotteau, Vincent
    Ruggieri, Alessia
    Bartenschlager, Ralf
    JOURNAL OF HEPATOLOGY, 2015, 63 (04) : 829 - 837
  • [50] Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus
    Lodrini, S
    Bagaglio, S
    Canducci, F
    De Mitri, MS
    Andreone, P
    Loggi, E
    Lazzarin, A
    Clementi, M
    Morsica, G
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2003, 17 (02) : 198 - 204